share_log

Akoya Biosciences and NeraCare Enter Into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions

Akoya Biosciences and NeraCare Enter Into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions

Akoya Biosciences和NeraCare簽署了一項獨家全球貨幣許可協議,用於開發和商業化針對早期黑色素瘤患者治療決策的Immunoprint測試。
GlobeNewswire ·  12/10 21:15

Akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize NeraCare's Immunoprint test for prognostication of disease recurrence in early-stage melanoma patients to better guide treatment decisions and potentially increase access to life saving therapies for those patients at high risk of developing metastatic disease

Akoya擴展臨床測試菜單,獨家獲得全球開發和商業化NeraCare免疫印刷測試的權利,以預測早期黑色素瘤患者疾病復發,從而更好地指導治療決策,並可能增加高風險發展轉移性疾病患者獲得生命救助療法的機會。

MARLBOROUGH, Mass. and FRANKFURT, Germany, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company, and NeraCare, a leading developer of laboratory tests for the prognosis of melanoma, today announced an exclusive global license agreement to develop and commercialize NeraCare's Immunoprint test on Akoya's multiplexed immunofluorescent platform. Building on the research collaboration between the companies announced earlier this year, the license agreement grants Akoya the exclusive right to develop, market and commercialize the test for clinical research, diagnostic development or, following regulatory approval, patient clinical testing as both a laboratory test or a distributable diagnostic on Akoya's PhenoImager HT platform.

馬爾伯勒(馬薩諸塞州)和德國法蘭克福,2024年12月10日(環球新聞網)-- Akoya Biosciences, Inc.(納斯達克:AKYA),空間生物學公司,以及NeraCare,一家領先的黑色素瘤預後實驗室測試開發商,今天宣佈達成獨家全球許可協議,以在Akoya的多重免疫熒光平台上開發和商業化NeraCare的免疫印刷測試。基於今年早些時候宣佈的公司間研究合作,該許可協議授予Akoya獨家權利,以開發、營銷和商業化該測試,用於臨床研究、診斷開發,或在獲得監管批准後,作爲實驗室測試或可分發的診斷,在Akoya的PhenoImager Ht平台上進行患者臨床測試。

Melanoma, the leading cause of skin cancer, sees over 235,000 new diagnoses every year, 80% of which are in early-stage disease (IA/IB/IIA). While these early-stage patients undergo surgery and subsequent monitoring, they are ineligible to receive effective adjuvant therapies approved for later stage melanoma. NeraCare's Immunoprint assay addresses this critical unmet need by identifying early-stage melanoma patients at high risk of relapse, comparable to later-stage patients, making them ideally suited to potentially benefit from therapeutic options.

黑色素瘤是皮膚癌的主要原因,每年新診斷超過235,000例,其中80%發生在早期階段(IA/IB/IIA)。雖然這些早期患者接受手術和隨後的監測,但他們不符合接受針對晚期黑色素瘤批准的有效輔助療法的條件。NeraCare的Immunoprint檢測通過識別高風險復發的早期黑色素瘤患者,滿足了這一關鍵的未滿足需求,這些患者與晚期患者相比,非常適合潛在受益於治療選擇。

"The agreement builds on the complementary expertise of both companies: Akoya's market-leading multiplex immunofluorescence technology and NeraCare's innovative development and rigorous clinical validation of Immunoprint. Together, we aim to expand access to life-saving therapies for early-stage melanoma patients worldwide," said Friedrich Ackermann, Co-Founder of NeraCare.

「該協議建立在兩家公司互補的專業知識基礎上:阿科亞市場領先的多重免疫熒光技術和NeraCare對Immunoprint的創新開發及嚴格的臨床驗證。我們共同的目標是擴大全球早期黑色素瘤患者獲得救命療法的機會,」NeraCare的聯合創始人弗里德里希·阿克曼說道。

"Our collaboration is a testament to the versatility of Akoya's PhenoImager HT platform and the clinical impact spatial biology can deliver. Immunoprint has proven unparalleled in identifying high-risk melanoma patients through multiple clinical studies, and our partnership aims to offer a platform to address the unmet need for earlier therapeutic intervention," added Daniel von Janowski, Co-Founder of NeraCare.

「我們的合作證明了阿科亞的PhenoImager Ht平台的多樣性以及空間生物學能夠帶來的臨床影響。Immunoprint在多項臨床研究中被證明在識別高風險黑色素瘤患者方面無與倫比,我們的合作旨在提供一個平台,以滿足對早期治療干預的未滿足需求,」NeraCare的聯合創始人丹尼爾·馮·揚諾夫斯基補充道。

"Our exclusive partnership with NeraCare for Immunoprint is a significant advancement of our clinical strategy providing Akoya and our pharmaceutical partners the opportunity to transform melanoma patient care We are honored to be partnering with NeraCare to help bring this test to market and serve a critical unmet need," said Brian McKelligon, CEO of Akoya Biosciences.

「我們與NeraCare在免疫打印方面的獨家合作是我們臨床策略的重要進展,爲Akoya和我們的製藥合作伙伴提供了改變黑色素瘤患者護理的機會。我們榮幸與NeraCare合作,幫助將這一檢測推向市場,以滿足至關重要的未滿足需求,」Akoya Biosciences首席執行官Brian McKelligon表示。

Forward-Looking Statements

前瞻性聲明

This press release contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements concerning our expectations about the potential, utility and safety of Immunoprint, our ability to develop, achieve regulatory approval, commercialize and achieve market acceptance of Immunoprint, the potential impact of Immunoprint on patient treatment and outcomes, and other matters regarding our business strategies, future performance, collaborations and plans and objectives for future operations.

本新聞稿包含基於管理層信念和假設以及目前可用信息的前瞻性陳述。此發佈中包含的所有除歷史事實聲明以外的聲明均爲前瞻性陳述,包括涉及我們對免疫打印的潛力,效用和安全性的預期,開發,獲得監管批准,商業化和實現免疫打印市場接受的能力,免疫打印對患者治療和結果的潛在影響,以及與我們業務策略,未來績效,合作以及未來操作的計劃和目標相關的其他事項的聲明。

In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

在某些情況下,您可以通過「可能」、「將」、「能夠」、「會」、「應該」、「期望」、「打算」、「計劃」、「預期」、「相信」、「估計」、「預測」、「項目」、「潛在」、「繼續」、「正在進行」或這些詞的否定形式或其他可比較術語來識別前瞻性陳述,儘管並非所有前瞻性陳述都包含這些詞。這些陳述涉及風險,不確定性和其他因素,可能導致實際結果,活動水平,表現或成就與這些前瞻性陳述中所表達或隱含的信息有實質性不同。這些風險,不確定性和其他因素在「風險因素」,「管理層對財務狀況和運營結果的討論與分析」以及我們不時向證券交易委員會提交的文件中進行了描述。我們提醒您,前瞻性陳述是基於我們目前已知的一系列事實和因素以及我們對未來的預測,而我們對此不能確定。因此,前瞻性陳述可能無法準確反映。本新聞稿中的前瞻性陳述代表了我們截至目前的觀點。除法律要求外,我們沒有義務更新任何前瞻性陳述。

About Akoya Biosciences

關於Akoya生物科學

As The Spatial Biology Company, Akoya Biosciences' mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit .

作爲空間生物學公司,Akoya生物科學的使命是通過空間表型的力量爲生物學和盈健醫療的世界帶來背景。該公司提供全面的單細胞成像解決方案,使研究人員能夠在空間背景下對細胞進行表型分析,並可視化它們如何組織和相互作用,從而影響疾病進展和對治療的反應。Akoya提供全方位的空間表型解決方案,以滿足研究人員在發現、轉化和臨床研究中的多樣化需求:PhenoCode面板和PhenoCycler,PhenoImager Fusion和PhenoImager Ht儀器。要了解更多關於Akoya的信息,請訪問。

About NeraCare

關於NeraCare

NeraCare is a developer of laboratory tests for individualized survival prediction of melanoma patients with offices in Frankfurt, Germany and New York, USA. The current portfolio includes two assays: (i) immunoprint, an immunohistochemistry-based assay which identifies patients with early-stage melanoma who are at high-risk of relapse and death and (ii) MelaGenix, a gene-expression-based assay which was used as an inclusion criterion in the NivoMela trial. NivoMela is the first clinical trial in melanoma to select patients for adjuvant treatment based on individualized risk for relapse. To date, NeraCare has raised $20+ million in venture capital financing.

NeraCare是一家開發實驗室檢測以對黑色素瘤患者進行個體化生存預測的公司,總部位於德國法蘭克福和美國紐約。目前的產品組合包括兩種檢測:(i)immunoprint,一種基於免疫組化的檢測,識別處於高復發和死亡風險的早期黑色素瘤患者;(ii)MelaGenix,一種基因表達基礎的檢測,該檢測在NivoMela 臨床試驗中被用作納入標準。NivoMela是黑色素瘤中第一項根據個體復發風險選擇患者進行輔助治療的臨床試驗。至今,NeraCare已籌集超過2000萬美元的創投融資。

Investor Contact:

投資者聯繫人:

Priyam Shah
investors@akoyabio.com

普里亞姆·沙
investors@akoyabio.com

Media Contact:

媒體聯繫人:

Christine Quern
cq@christinequern.com

克莉絲汀·庫恩
cq@christinequern.com


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論